Skip to main content
Journal cover image

Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.

Publication ,  Journal Article
Herring, WJ; Connor, KM; Ivgy-May, N; Snyder, E; Liu, K; Snavely, DB; Krystal, AD; Walsh, JK; Benca, RM; Rosenberg, R; Sangal, RB; Budd, K ...
Published in: Biol Psychiatry
January 15, 2016

BACKGROUND: Suvorexant is an orexin receptor antagonist for treatment of insomnia. We report results from two pivotal phase 3 trials. METHODS: Two randomized, double-blind, placebo-controlled, parallel-group, 3-month trials in nonelderly (18-64 years) and elderly (≥65 years) patients with insomnia. Suvorexant doses of 40/30 mg (nonelderly/elderly) and 20/15 mg (nonelderly/elderly) were evaluated. The primary focus was 40/30 mg, with fewer patients randomized to 20/15 mg. There was an optional 3-month double-blind extension in trial 1. Each trial included a 1-week, randomized, double-blind run-out after double-blind treatment to assess withdrawal/rebound. Efficacy was assessed at week 1, month 1, and month 3 by patient-reported subjective total sleep time and time to sleep onset and in a subset of patients at night 1, month 1, and month 3 by polysomnography end points of wakefulness after persistent sleep onset and latency to onset of persistent sleep (LPS). One thousand twenty-one patients were randomized in trial 1 and 1019 patients in trial 2. RESULTS: Suvorexant 40/30 mg was superior to placebo on all subjective and polysomnography end points at night 1/week 1, month 1, and month 3 in both trials, except for LPS at month 3 in trial 2. Suvorexant 20/15 mg was superior to placebo on subjective total sleep time and wakefulness after persistent sleep onset at night 1/week 1, month 1, and month 3 in both trials and at most individual time points for subjective time to sleep onset and LPS in each trial. Both doses of suvorexant were generally well tolerated, with <5% of patients discontinuing due to adverse events over 3 months. The results did not suggest the emergence of marked rebound or withdrawal signs or symptoms when suvorexant was discontinued. CONCLUSIONS: Suvorexant improved sleep onset and maintenance over 3 months of nightly treatment and was generally safe and well tolerated.

Duke Scholars

Published In

Biol Psychiatry

DOI

EISSN

1873-2402

Publication Date

January 15, 2016

Volume

79

Issue

2

Start / End Page

136 / 148

Location

United States

Related Subject Headings

  • Wakefulness
  • Triazoles
  • Treatment Outcome
  • Sleep Initiation and Maintenance Disorders
  • Sleep
  • Psychiatry
  • Polysomnography
  • Orexin Receptor Antagonists
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Herring, W. J., Connor, K. M., Ivgy-May, N., Snyder, E., Liu, K., Snavely, D. B., … Michelson, D. (2016). Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. Biol Psychiatry, 79(2), 136–148. https://doi.org/10.1016/j.biopsych.2014.10.003
Journal cover image

Published In

Biol Psychiatry

DOI

EISSN

1873-2402

Publication Date

January 15, 2016

Volume

79

Issue

2

Start / End Page

136 / 148

Location

United States

Related Subject Headings

  • Wakefulness
  • Triazoles
  • Treatment Outcome
  • Sleep Initiation and Maintenance Disorders
  • Sleep
  • Psychiatry
  • Polysomnography
  • Orexin Receptor Antagonists
  • Middle Aged
  • Male